Andrx Names Lawrence Rosenthal President of Andrx Pharmaceuticals, Inc.

Business Editors/Health/Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Sept. 19, 2003

Andrx Corporation (Nasdaq:ADRX) ("Andrx" or the "Company") announced today the promotion of Lawrence Rosenthal to the position of President of Andrx Pharmaceuticals, Inc. ("Andrx Pharmaceuticals"), reporting directly to Andrx's Chief Executive Officer, Richard J. Lane. As President of Andrx Pharmaceuticals, Mr. Rosenthal will be responsible for Andrx's generic operations.

Richard Lane, Chief Executive Officer of Andrx, said: "I am delighted to have an executive of Larry's caliber as part of my management team. Over the past five years, he has made a substantial contribution to our overall growth and this promotion is an acknowledgement of his accomplishments. With his new responsibilities, I am highly confident that he will play an even more prominent role in our future growth."

Mr. Rosenthal joined Andrx in January 1999 as Executive Vice President Sales & Marketing of Andrx Pharmaceuticals. Prior to joining Andrx, Mr. Rosenthal was employed for 12 years by Teva Pharmaceuticals USA, one of the leading generic pharmaceutical companies in the United States, last serving as Vice President of Sales & Marketing. Mr. Rosenthal is also a member of the board of directors of the Generic Pharmaceutical Association ("GPhA").

About Andrx Corporation

Andrx Corporation develops and commercializes: bioequivalent versions of controlled-release brand name pharmaceuticals using its proprietary drug delivery technologies; bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives; and brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs where it believes the application of Andrx's drug delivery technologies may improve the efficacy or other characteristics of those products. Andrx's distribution operations purchase primarily generic pharmaceuticals manufactured by third parties and sells them primarily to independent pharmacies, pharmacy chains which do not maintain their own central warehousing facilities, pharmacy buying groups and, to a lesser extent, physicians' offices.

Forward looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the success of Mr. Rosenthal and the Company's generic operations, as well as the Company's dependence on a relatively small number of products, the timing and outcome of litigation and future product launches, government regulation, competition, and manufacturing results. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission.

This release and additional information about Andrx Corporation is also available on the Internet at: http://www.andrx.com.